Injectable Male Contraceptive "ADAM" Human Trial Results Show Long-Term Efficacy

A New Option Beyond the Vasectomy

For decades, the burden of long-term contraception has fallen almost exclusively on women. Men seeking a more permanent solution than condoms have traditionally had only one option: the vasectomy. While highly effective, a vasectomy is a surgical procedure that is often difficult to reverse, creating a significant barrier for men who may want children later in life.

Results from the first-in-human trials of ADAM, a non-hormonal, injectable hydrogel, suggest that a third, reversible option is finally within reach. Presented at the American Urological Association (AUA) 2025 Annual Meeting, the data confirms that this innovative method can effectively block sperm for at least 24 months.

Developed by the biotech firm Contraline, ADAM is a water-soluble hydrogel injected into the vas deferens — the tubes that carry sperm from the testicles. Unlike a vasectomy, which involves cutting or cauterizing these tubes, ADAM acts as a physical filter. The hydrogel is designed to allow the passage of seminal fluid while trapping the larger sperm cells. This mechanism effectively renders the user infertile without the need for hormonal manipulation. The procedure is minimally invasive, typically taking roughly 10 minutes under local anaesthesia, much like a no-scalpel vasectomy.

The Scientific Findings

The Phase 1 clinical trial, led by Professor Nathan Lawrentschuk of the University of Melbourne, monitored 25 healthy men to assess safety and efficacy. The initial 90-day analysis showed that all 50 implantations (one for each vas deferens per patient) were successful with no procedural adverse events. By the 24-month mark, investigators reported that participants had achieved azoospermia — the total absence of motile sperm in the ejaculate.

"These findings confirm that ADAM can achieve its intended lifespan of two years," stated Dr. Alexander Pastuszak, Chief Medical Officer at Contraline. The trial found that 84% of reported side effects were mild and consistent with standard recovery from minor urological procedures, such as slight tenderness or bruising. Importantly, there were no reported changes in libido or sexual function, a common concern with hormonal male contraceptives currently in development.

Why This Matters for Sexual Health

The "holy grail" of male contraception has long been a method that is as reliable as a vasectomy but as reversible as an IUD. While hormonal male pills have historically struggled with side effects like mood swings, weight gain, and acne, ADAM is entirely non-hormonal. This means it does not interfere with the hypothalamic-pituitary-gonadal axis or natural testosterone levels.

As the trial moves into Phase 2, researchers are focusing on the "liquification" process — the point at which the hydrogel naturally breaks down or is dissolved by a second injection to restore fertility. This breakthrough represents a major shift toward shared reproductive responsibility and offers men a level of autonomy previously unavailable in the contraceptive landscape.